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Introduction {#jdi12916-sec-0005}
============

Currently, the number of patients with diabetes is increasing worldwide, and it is well known that diabetes give rise to various complications[1](#jdi12916-bib-0001){ref-type="ref"}. To prevent these complications, maintaining a good blood glucose level is required[2](#jdi12916-bib-0002){ref-type="ref"}, [3](#jdi12916-bib-0003){ref-type="ref"}. Both exercise and diet therapies are the main therapies; however, it is difficult to achieve a good blood glucose level with these therapies only in patients with type 2 diabetes[4](#jdi12916-bib-0004){ref-type="ref"}. Thus, to achieve a good blood glucose level, many patients with type 2 diabetes receive a medication therapy[4](#jdi12916-bib-0004){ref-type="ref"}. Regardless of these various approaches, many patients cannot achieve a good blood glucose level[5](#jdi12916-bib-0005){ref-type="ref"}.

One of the reasons why many patients cannot achieve a good blood glucose level is poor medication adherence[6](#jdi12916-bib-0006){ref-type="ref"}. The risk of diabetic complications was reduced by proper use of antidiabetic medications, and medication adherence reinforces the effect of medications[7](#jdi12916-bib-0007){ref-type="ref"}. In fact, medication adherence affects the blood glucose level[4](#jdi12916-bib-0004){ref-type="ref"}, [8](#jdi12916-bib-0008){ref-type="ref"}, [9](#jdi12916-bib-0009){ref-type="ref"}, [10](#jdi12916-bib-0010){ref-type="ref"}.

In contrast, it is reported that an understanding of medications prescribed for patients is associated with their medication adherence[11](#jdi12916-bib-0011){ref-type="ref"}. Although some previous studies reported the relationship between medication adherence and blood glucose level, no previous studies reported the relationship between the understanding of antidiabetic medications and blood glucose level in patients with type 2 diabetes[12](#jdi12916-bib-0012){ref-type="ref"}. Thus, we examined the relationship between the understanding of antidiabetic medications and blood glucose level in patients with type 2 diabetes at the baseline date of the KAMOGAWA‐DM cohort study.

Methods {#jdi12916-sec-0006}
=======

Patients and study design {#jdi12916-sec-0007}
-------------------------

The KAMOGAWA‐DM cohort study, which was started to elucidate the natural history of patients with diabetes from 2014, is an ongoing cohort study of patients with diabetes[12](#jdi12916-bib-0012){ref-type="ref"}. We gave informed consent to all patients for this cohort study, and we recorded patients' medical data into a database after eliminating personal identification information. In this cross‐sectional study, we enrolled the outpatients at the Kyoto Prefectural University of Medicine (Kyoto, Japan), from January 2014 to January 2016. Patients who used steroid treatment, with active malignancy, with severe renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m^2^)[13](#jdi12916-bib-0013){ref-type="ref"}, after a renal transplantation, after a liver transplantation and with missing data of covariates were excluded from the present study. We also excluded patients who attended a hospital for psychosis, because they could not take medication regularly; and patients whose answer for insulin use showed a discrepancy to actual use in the questionnaire, because their answer was not credible. In addition, we excluded the patients with anemia whose hemoglobin concentration was \<11 g/dL[14](#jdi12916-bib-0014){ref-type="ref"}, because anemia affects hemoglobin A1c (HbA1c) levels. Approval for this study was obtained from the Ethics Committee of Kyoto Prefectural University of Medicine (No. RBMR‐E‐466‐1).

Questionnaire and measurements {#jdi12916-sec-0008}
------------------------------

Lifestyle factors were assessed by a questionnaire survey, including "Do you take antidiabetic medications?". Current treatments data, including medications for diabetes and total number of oral medications, were gathered from medical records. In regard to the exercise status, we defined the patients who did any sports once a week regularly as regular exercisers[15](#jdi12916-bib-0015){ref-type="ref"}. In regard to alcohol, we defined patients who drank alcohol daily as alcohol drinkers. In regard to smoking, patients were categorized into three groups; never‐smoker, ex‐smoker or current smoker[16](#jdi12916-bib-0016){ref-type="ref"}. We defined a poor understanding of antidiabetic medication (PUAD) as the answer to the question "Do you take antidiabetic medications?" being inconsistent with the actual prescriptions on the questionnaire (Figure [S1](#jdi12916-sup-0001){ref-type="supplementary-material"}).

Body mass index was calculated as weight in kilograms divided by height in meters squared. We collect the venous blood after an overnight fast, and we checked the levels of several factors, including total cholesterol, high‐density lipoprotein cholesterol, triglycerides, fasting plasma glucose, gamma‐glutamyltransferase, aspartate aminotransferase, alanine aminotransferase, uric acid and creatinine. Glomerular filtration rate was approximated by the Japanese Society of Nephrology equation: estimated glomerular filtration rate (mL/min/1.73 m^2^) = 194 × serum creatinine^−1.094^ × age^−0.287^ (×0.739 for women)[17](#jdi12916-bib-0017){ref-type="ref"}. The National Glycohemoglobin Standardization Program unit was used for HbA1c, and we defined HbA1c ≥8% (63 mmol/mol) as a poor blood glucose level[18](#jdi12916-bib-0018){ref-type="ref"}.

We assessed the relationship between the poor understanding of antidiabetic medication and the prevalence of microvascular complications, which included diabetic nephropathy and diabetic neuropathy. As for diabetic nephropathy, we divided patients into three groups according to the urinary albumin excretion level: \<30 mg/g, 30--300 mg/g and \<300 mg/g creatinine[19](#jdi12916-bib-0019){ref-type="ref"}. In regard to diabetic neuropathy, we judged the presence of diabetic nephropathy by assessing whether the attending physician had diagnosed neuropathy in medical record (Figure [1](#jdi12916-fig-0001){ref-type="fig"}).

![Inclusion and exclusion flow.](JDI-10-458-g001){#jdi12916-fig-0001}

We also examined the diabetic medications and categorized them as follows: insulin secretagogues, incretin‐based therapy, insulin sensitizers, nutrient load reducers and insulin. We categorized sulfonylureas and glinides into insulin secretagogues, dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonist into incretin‐based therapy, pioglitazone and metformin into insulin sensitizers, and α‐glucosidase inhibitors and sodium‐glucose cotransporter inhibitors into nutrient load reducers.

Statistical analysis {#jdi12916-sec-0009}
--------------------

Statistical analyses were carried out using JMP version 12.0 software (SAS Institute, Cary, NC, USA), and *P *\<* *0.05 was defined as significant statistically. We calculated the mean, median and frequencies of variables. Continuous variables were shown as the mean (standard deviation \[SD\]), and if the variables were skewed, as the median (interquartile range). Student\'s *t*‐test or the Mann--Whitney *U*‐test were used to evaluate statistical significance of differences between groups. Category variables were shown as the number. The χ^2^‐test was used to evaluate statistical significance of differences between groups.

Univariate logistic regression analyses were carried out to evaluate the effect of various factors, including PUAD, on poor blood glucose level.

In the present study, 94 (19.6%) patients had a poor blood glucose level. Because this number of patients might be small for statistical analysis, we used propensity scores, which preserved statistical power by reducing the covariates into a single variable. For the assessment of the propensity score, the dependent variable was the PUAD. The propensity score was evaluated using multivariable logistic regression models that included the following parameters: sex, age, log (duration of diabetes +1), body mass index, number of oral antidiabetic medications, smoking status, alcohol drinking, exercise, nephropathy, neuropathy, insulin secretagogues, incretin‐based therapy, insulin sensitizers, nutrient load reducers and insulin.

The c‐statistic for the propensity score model was 0.80, which shows an acceptable discrimination. Then, 1:1 matching on the propensity score was carried out using nearest neighbor matching with a maximum caliper of 0.05 of the propensity score. Finally, 74 patients were selected for the propensity‐matched population, and we calculated the odds ratio for poor blood glucose level by logistic regression analysis.

Results {#jdi12916-sec-0010}
=======

A total of 638 patients (398 men and 240 women) were enrolled into the present cross‐sectional study. Then, 159 patients (93 men and 66 women) were excluded. Thus, 479 patients (305 men and 174 women) were selected for this study.

Table [1](#jdi12916-tbl-0001){ref-type="table"} shows the clinical characteristics of the overall study patients according to the presence of PUAD. The mean age and median of duration of diabetes (interquartile range) were 68.4 years (SD 10.4 years) and 12 years (SD 7--20 years), respectively. The mean HbA1c was 7.2% (SD 1.0%; 55.3 mmol/mol \[SD 10.6 mmol/mol\]), and 94 patients (20%) were categorized as having a poor blood glucose level. A total of 281 patients (59%) had hypertension, and 425 patients (89%) use medication for diabetes. The mean total number of oral medications and the number of oral antidiabetic medications were 5.4 (SD 3.3) and 1.7 (SD 1.2), respectively. In addition, 40 patients (8.4%) were categorized into the PUAD group. The HbA1c of patients with PUAD was higher than that of patients without (7.5% \[SD 1.3%\] vs 7.2% \[SD 0.9%\], *P *=* *0.041 \[58.5 mmol/mol (SD 14.0 mmol/mol) vs 55.0 mmol/mol (SD 10.2 mmol/mol)\]). The number of antidiabetic medications of patients with PUAD was lower than that of patients without (1.1 \[SD 1.0\] vs 1.7 \[SD 1.2\], *P *=* *0.001).

###### 

Clinical characteristics of overall study patients according to the presence of a poor understanding of antidiabetic medication

                                                           Total            Poor understanding of antidiabetic medication (−)   Poor understanding of antidiabetic medication (+)   *P*
  -------------------------------------------------------- ---------------- --------------------------------------------------- --------------------------------------------------- -------
  *n*                                                      479              439                                                 40                                                  --
  Men/women (*n*)                                          305/174          271/168                                             34/6                                                0.003
  Age (years)                                              68.4 (10.4)      68.7 (10.1)                                         65.5 (13.1)                                         0.063
  Duration of diabetes (years)                             12 (7--20)       12 (7--20)                                          15 (6--20)                                          0.282
  Body mass index (kg/m^2^)                                23.6 (3.7)       23.6 (3.7)                                          23.9 (3.3)                                          0.579
  Hypertension (−/+)                                       198/281          183/256                                             15/25                                               0.607
  Hemoglobin A1c (%)                                       7.2 (1.0)        7.2 (0.9)                                           7.5 (1.3)                                           0.041
  Hemoglobin A1c (mmol/mol)                                55.3 (10.6)      55.0 (10.2)                                         58.5 (14.0)                                         0.041
  Poor blood glucose level (−/+)                           385/94           358/81                                              27/13                                               0.032
  Fasting plasma glucose (mmol/L)                          8.0 (2.3)        7.9 (2.2)                                           8.3 (3.8)                                           0.278
  Total cholesterol (mmol/L)                               4.7 (0.9)        4.8 (0.9)                                           4.4 (0.8)                                           0.025
  Triglycerides (mmol/L)                                   1.2 (0.8--1.7)   1.2 (0.8--1.7)                                      1.3 (0.8--1.8)                                      0.839
  HDL cholesterol (mmol/L)                                 1.5 (0.4)        1.6 (0.4)                                           1.4 (0.4)                                           0.049
  Aspartate aminotransferase (IU/L)                        25.4 (12.7)      25.5 (13.0)                                         24.2 (10.0)                                         0.521
  Alanine aminotransferase (IU/L)                          24.0 (17.4)      24.0 (17.7)                                         23.4 (14.4)                                         0.829
  Gamma‐glutamyltransferase (IU/L)                         26 (18--41)      25 (18--41)                                         30 (21--37)                                         0.408
  Creatinine (μmol/L)                                      70.4 (20.9)      70.0 (20.9)                                         73.8 (21.0)                                         0.279
  eGFR (mL/min/1.73 m^2^)                                  72.3 (18.6)      72.1 (18.5)                                         74.1 (19.1)                                         0.514
  Uric acid (μmol/L)                                       315 (77)         316 (77)                                            306 (79)                                            0.460
  Exercise (−/+)                                           221/258          203/236                                             18/22                                               0.880
  Never‐/ex‐/current‐smoker (*n*)                          187/225/67       172/208/59                                          15/17/8                                             0.512
  Alcohol drinking (−/+)                                   360/119          333/106                                             27/13                                               0.242
  Nephropathy (UAE \<30/30--300/\<300 mg/g creatinine)     300/123/56       275/116/48                                          25/7/8                                              0.156
  Neuropathy (−/+)                                         343/136          319/120                                             24/16                                               0.089
  Medication usage for diabetes (−/+)                      54/425           47/392                                              7/33                                                0.193
  Total no. oral medication                                5.4 (3.3)        5.4 (3.3)                                           5.6 (4.0)                                           0.667
  No. oral antidiabetic medication                         1.7 (1.2)        1.7 (1.2)                                           1.1 (1.0)                                           0.001
  No. oral medication other than antidiabetic medication   3.7 (3.1)        3.6 (3.1)                                           4.5 (3.7)                                           0.097
  Insulin (−/+)                                            387/92           356/83                                              31/9                                                0.581
  Insulin secretagogues (−/+)                              230/249          202/237                                             28/12                                               0.004
  Incretin‐based therapy (−/+)                             170/309          152/287                                             18/22                                               0.189
  Insulin sensitizers (−/+)                                290/189          261/178                                             29/11                                               0.106
  Nutrient load reducers (−/+)                             399/80           364/75                                              35/5                                                0.457

Data are expressed as mean (standard deviation), median (interquartile range) or number. Poor blood glucose level was defined as hemoglobin A1c (HbA1c) ≥8.0%. The difference between groups was analyzed by Student\'s *t*‐test, Mann--Whitney *U*‐test or the χ^2^‐test. eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; UAE, urinary albumin excretion.
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Table [2](#jdi12916-tbl-0002){ref-type="table"} shows the unadjusted odds ratios of various factors for poor blood glucose levels for the overall patient cohort. PUAD (odds ratio 2.13, 95% confidence interval 1.02--4.23, *P *=* *0.044) was associated with poor blood glucose level.

###### 

Unadjusted odds ratios for poor blood glucose level in overall patients

                                                  Odds ratio (95% CI)   *P*
  ----------------------------------------------- --------------------- ---------
  Sex                                             1.13 (0.71--1.84)     0.606
  Age                                             0.98 (0.96--1.00)     0.035
  Log (duration of diabetes +1)                   4.58 (2.12--10.36)    \<0.001
  Body mass index                                 1.09 (1.03--1.16)     0.005
  No. oral antidiabetic medication                1.54 (1.27--1.88)     \<0.001
  Smoking status                                                        
  Never‐smoker                                    Ref                   --
  Ex‐smoker                                       0.90 (0.55--1.47)     0.673
  Current‐smoker                                  1.04 (0.51--2.03)     0.921
  Alcohol drinking                                0.84 (0.48--1.42)     0.527
  Exercise                                        0.60 (0.38--0.94)     0.026
  Insulin                                         2.28 (1.35--3.79)     0.002
  Insulin secretagogues                           1.73 (1.09--2.78)     0.019
  Incretin based therapy                          2.19 (1.32--3.79)     0.002
  Insulin sensitizers                             1.81 (1.15--2.85)     0.011
  Nutrient load reducers                          2.17 (1.25--3.70)     0.006
  Poor understanding of antidiabetic medication   2.13 (1.02--4.23)     0.044

Odds ratios given with 95% confidence intervals (CI) express the risk associated with 1‐unit increase in each continuous variable. As for smoking status, never‐smoker was used as reference group. Log, logarithm.
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Table [3](#jdi12916-tbl-0003){ref-type="table"} shows clinical characteristics of propensity‐matched 74 patients (62 men and 12 women) according to the presence of PUAD. The mean age (SD) and median of duration of diabetes (interquartile range) were 66.3 (13.1) years and 15 (7--23) years, respectively. Clinical characteristics were not different between groups without the ratio of poor blood glucose level (32% (case/*n* = 12/37) in patients with PUAD vs 8% (case/*n* = 3/37) in patients without, *P *=* *0.009). In addition, PUAD was associated with poor blood glucose level (odds ratio: 5.45, 95% confidence interval 1.54--25.8, *P *=* *0.007) by logistic regression analysis.

###### 

Clinical characteristics of propensity‐matched patients according to the presence of a poor understanding of antidiabetic medication

                                                           Poor understanding of antidiabetic medication (−)   Poor understanding of antidiabetic medication (+)   *P*
  -------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- -------
  *n*                                                      37                                                  37                                                  --
  Men/women (*n*)                                          31/6                                                31/6                                                1.0
  Age (years)                                              67.1 (13.3)                                         65.5 (13.1)                                         0.600
  Duration of diabetes (years)                             14 (7--25)                                          15 (6--20)                                          0.992
  Body mass index (kg/m^2^)                                24.3 (4.8)                                          24.0 (3.4)                                          0.732
  Hypertension (−/+)                                       13/24                                               14/23                                               0.809
  Poor blood glucose level (−/+)                           34/3                                                25/12                                               0.009
  Fasting plasma glucose (mmol/L)                          7.9 (2.3)                                           8.3 (3.9)                                           0.576
  Total cholesterol (mmol/L)                               4.8 (1.2)                                           4.5 (0.8)                                           0.172
  Triglycerides (mmol/L)                                   1.2 (0.8--1.7)                                      1.2 (0.8--1.8)                                      0.347
  HDL cholesterol (mmol/L)                                 1.5 (0.4)                                           1.4 (0.4)                                           0.421
  Aspartate aminotransferase (IU/L)                        22 (20--27)                                         22 (18--28)                                         0.539
  Alanine aminotransferase (IU/L)                          18 (15--28)                                         19 (14--27)                                         0.916
  Gamma‐glutamyltransferase (IU/L)                         29 (18--43)                                         30 (21--38)                                         0.864
  Creatinine (μmol/L)                                      79.9 (28.7)                                         72.5 (21.0)                                         0.209
  eGFR (mL/min/1.73 m^2^)                                  70.6 (25.0)                                         75.3 (19.1)                                         0.366
  Uric acid (μmol/L)                                       324 (92)                                            303 (80)                                            0.309
  Exercise (−/+)                                           17/20                                               17/20                                               1.0
  Never‐/ex‐/current‐smoker (*n*)                          11/16/10                                            13/17/7                                             0.696
  Alcohol drinking (−/+)                                   26/11                                               25/12                                               0.802
  Nephropathy (UAE \<30/30--300/\<300 mg/g)                22/9/6                                              25/6/6                                              0.673
  Neuropathy (−/+)                                         24/13                                               23/14                                               0.809
  Medication use for diabetes (−/+)                        5/32                                                6/31                                                0.744
  Total no. oral medication                                5.1 (3.6)                                           5.8 (4.1)                                           0.401
  No. oral antidiabetic medication                         1.1 (0.9)                                           1.2 (1.0)                                           0.712
  No. oral medication other than antidiabetic medication   4.0 (3.5)                                           4.6 (3.8)                                           0.431
  Insulin (−/+)                                            27/10                                               29/8                                                0.588
  Insulin secretagogues (−/+)                              30/7                                                25/12                                               0.183
  Incretin based therapy (−/+)                             15/22                                               16/21                                               0.814
  Insulin sensitizers (−/+)                                28/9                                                27/10                                               0.790
  Nutrient load reducers (−/+)                             33/4                                                32/5                                                0.722

Data are expressed as mean (standard deviation), median (interquartile range) or number. The difference between groups was analyzed by Student\'s *t*‐test, Mann--Whitney *U*‐test or the χ^2^‐test. The propensity score was evaluated using multivariable logistic regression models that include the following parameters: sex, age, log (duration of diabetes +1), body mass index, number of oral antidiabetic medications, smoking status, alcohol drinking, exercise, nephropathy, neuropathy, insulin, insulin secretagogues, incretin‐based therapy, insulin sensitizers and nutrient load reducers. eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; UAE, urinary albumin excretion.
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Discussion {#jdi12916-sec-0011}
==========

The present study shows that PUAD was associated with poor blood glucose levels in patients with type 2 diabetes. The proportion of patients with PUAD was 8.4% in this study. It was reported that half of the patients, who suffered chronic disease, had low adherence[20](#jdi12916-bib-0020){ref-type="ref"}. In addition, it was reported that 15--33% of patients with diabetes did not take prescribed antidiabetic medications, and that of the patients with poor blood glucose level, three‐fifths of patients did not take prescribed antidiabetic medications[5](#jdi12916-bib-0005){ref-type="ref"}, [21](#jdi12916-bib-0021){ref-type="ref"}. Medication adherence consisted of many factors, such as an understanding of medications, duration of disease, age, polypharmacy, tolerability and cost[4](#jdi12916-bib-0004){ref-type="ref"}, [22](#jdi12916-bib-0022){ref-type="ref"}. Although the relationship between medication adherence and glycemic control was reported in the past[6](#jdi12916-bib-0006){ref-type="ref"}, no previous studies clarified the relationship between an understanding of antidiabetic medications and blood glucose level. This is the first study to clarify the relationship between an understanding of antidiabetic medications and blood glucose level in patients with type 2 diabetes.

Low medication adherence was reported to result in poor glycemic control[6](#jdi12916-bib-0006){ref-type="ref"}. Medication adherence consisted of many factors, including an understanding of medications[22](#jdi12916-bib-0022){ref-type="ref"}. Poor understanding of medications was correlated with low knowledge of each disease[23](#jdi12916-bib-0023){ref-type="ref"}. As for diabetes, it was reported that an understanding of medications, through having knowledge of diabetes[24](#jdi12916-bib-0024){ref-type="ref"}, affects medication adherence, which is associated with blood glucose level.

It was reported that the rate of exercise therapy of patients was affected by the understanding of the knowledge of diabetes, including diabetic medications[25](#jdi12916-bib-0025){ref-type="ref"}. In the present study, among patients with type 2 diabetes, there was no significant difference between the ratio of regular exercise for patients with PUAD and without (55% \[case/*n* = 22/40\] vs 54% \[case/*n* = 236/439\], *P *=* *0.880). Exercise therapy was affected by environmental factors, including family support[26](#jdi12916-bib-0026){ref-type="ref"}. There is a possibility that these environmental factors might lead to a similarity in the habit of regular exercise between patients with a poor understanding of medication and those with a good understanding**.**

Generally, poor glycemic control is positively associated with microvascular complications of diabetes[1](#jdi12916-bib-0001){ref-type="ref"}. In the present study, there were no significant differences in the prevalence of diabetic nephropathy between patients with and without PUAD (*P *=* *0.156). As for diabetic neuropathy, the ratio of diabetic neuropathy in patients with PUAD tended to be higher than that in patients without PUAD (*P *=* *0.089). It was reported that microvascular complications of diabetes were associated with glycemic control, age, blood pressure and duration of diabetes[1](#jdi12916-bib-0001){ref-type="ref"}, [27](#jdi12916-bib-0027){ref-type="ref"}. In the present study, there were no significant differences in age, the prevalence of hypertension and the duration of diabetes between patients with and without PUAD, although glycemic control among patients with PUAD was higher than that of patients without. This might result in there being no significant difference in the prevalence of diabetic microangiopathy between patients with and without PUAD.

Furthermore, we showed the relationship between the number of oral antidiabetic medications and poor blood glucose level, which was almost same as previous studies[28](#jdi12916-bib-0028){ref-type="ref"}, [29](#jdi12916-bib-0029){ref-type="ref"}. In contrast, in the present study, the glucose level of patients with PUAD was higher than that of patients without, although patients with PUAD took fewer antidiabetic medications than patients without PUAD. One of the reasons is that PUAD itself causes poor medication adherence[23](#jdi12916-bib-0023){ref-type="ref"}.

Previous studies showed that there is a relationship between PUAD and the education of medical staff about antidiabetic medication[23](#jdi12916-bib-0023){ref-type="ref"}. Thus, education of medical staff might improve the blood glucose level of patients with PUAD through the improvement of PUAD[30](#jdi12916-bib-0030){ref-type="ref"}.

There are some limitations that should be mentioned. First, because of the cross‐sectional nature of the present study, the causal relationship between PUAD and poor blood glucose level was unclear. Second, we did not evaluate cognitive function. Thus, we cannot deny the possibility that an understanding of antidiabetic medication might have been affected by cognitive function. In fact, previous studies have shown that cognitive impairment and memory problems could play an important role in medication adherence[31](#jdi12916-bib-0031){ref-type="ref"}, [32](#jdi12916-bib-0032){ref-type="ref"}. However, in the present study, age and the duration of diabetes, which were generally associated with cognitive function in patients with type 2 diabetes[33](#jdi12916-bib-0033){ref-type="ref"}, were not significantly different between patients with PUAD and without. Thus, the influence of cognitive function might be small. Third, we did not evaluate the number of unused medicines. Therefore, increased unused medicine led by low medication adherence might have resulted in poor blood glucose level. However, unused medicine is also related to PUAD, because medication adherence is affected by an understanding of medications[30](#jdi12916-bib-0030){ref-type="ref"}. Fourth, only Japanese patients were included in the present study. Therefore, whether these results can be generalized to non‐Japanese patients with type 2 diabetes is uncertain. Fifth, as for the questionnaire used in the present study, there are no gold standard methods for such a questionnaire method in any languages, including Japanese.

In conclusion, the present cross‐sectional study shows, for the first time, that a poor understanding of antidiabetic medication is associated with poor blood glucose levels in patients with type 2 diabetes. In clinical practice of diabetes, we should consider the understanding of antidiabetic medications.

Disclosure {#jdi12916-sec-0013}
==========

Yoshitaka Hashimoto received grants support from the Fuji Foundation, Japan Society for the Promotion of Science, Asahi Kasei Pharma and MSD K.K. outside the submitted work. Masahiro Yamazaki received honoraria from AstraZeneca plc outside the submitted work. Michiaki Fukui reports grants from Japan Society for the Promotion of Science, AstraZeneca plc, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by a pharmaceutical company, the authors received no current funding for this study and this does not alter their adherence to all the journal policies on sharing data and materials. The other authors declare no conflict of interest.

Supporting information
======================

###### 

**Figure S1** ¦ Questionnaire used to define a poor understanding of antidiabetic medication (PUAD). The patients checked the check box according to the current treatment for diabetes. If the patients received several treatments, the patient checked several check boxes.

###### 

Click here for additional data file.
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